Eduardo Yáñez

机构：Universidad de La Frontera · ORCID：0000-0003-1839-5314

发表论文 41 篇 · 总被引 1038 次 · h-index 15

代表论文

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (2023 · JAMA Oncology · 被引 64)
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study (2024 · Annals of Oncology · 被引 57)
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. (2021 · Journal of Clinical Oncology · 被引 27)
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study (2024 · Gynecologic Oncology · 被引 24)
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. (2021 · Journal of Clinical Oncology · 被引 18)
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma (2024 · Blood Advances · 被引 17)